TERT promoter mutations in thyroid cancer

Endocrine-Related Cancer

Volumn 23, Issue 3, 2016, Pages R143-R155

  Liu, Rengyun ^a   Xing, Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF V600E mutation; Diagnosis; Genetic molecular marker; S prognosis; Telomerase reverse; TERT promoter mutation; Thyroid cancer; Transcriptase

Indexed keywords

B RAF KINASE; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; BRAF PROTEIN, HUMAN; RAS PROTEIN;

ANAPLASTIC THYROID CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; DISTANT METASTASIS; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; POORLY DIFFERENTIATED THYROID CANCER; PROMOTER REGION; REVIEW; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID TUMOR; GENETICS; MUTATION;

HUMANS; MUTATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TELOMERASE; THYROID NEOPLASMS;

EID: 84963959697     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-15-0533     Document Type: Review

References (77)

1. Asaad NY, Abd El-Wahed MM & Mohammed AG 2006 Human telomerase reverse transcriptase (hTERT) gene expression in thyroid carcinoma: diagnostic and prognostic role. Journal of the Egyptian National Cancer Institute 18 8-16.
2. Ballester LY, Sarabia SF, Sayeed H, Patel N, Baalwa J, Athanassaki I, Hernandez JA, Fang E, Quintanilla NM, Roy A et al. 2015 Integrating molecular testing in the diagnosis and management of children with thyroid lesions. Pediatric and Developmental Pathology [in press]. (doi:10.2350/15-05-1638-OA.1)
3. Bell RJ, Rube HT, Kreig A, Mancini A, Fouse SD, Nagarajan RP, Choi S, Hong C, He D, Pekmezci M et al. 2015 Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 348 1036-1039. (doi:10.1126/science.aab0015)
4. de Biase D, Gandolfi G, Ragazzi M, Eszlinger M, Sancisi V, Gugnoni M, Visani M, Pession A, Casadei G, Durante C et al. 2015 TERT promoter mutations in papillary thyroid microcarcinomas. Thyroid 25 1013-1019. (doi:10.1089/thy.2015.0101)
5. Blasco MA 2005 Telomeres and human disease: ageing, cancer and beyond. Nature Review Genetics 6 611-622. (doi:10.1038/nrg1656)
6. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S & Wright WE 1998 Extension of life-span by introduction of telomerase into normal human cells. Science 279 349-352. (doi:10.1126/science.279.5349.349)
7. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen HC, Smart CE et al. 2013 Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics 45 371-384. (doi:10.1038/ng.2566)
8. Cancer Genome Atlas Research Network 2014 Integrated genomic characterization of papillary thyroid carcinoma. Cell 159 676-690. (doi:10.1016/j.cell.2014.09.050)
9. Chindris AM, Casler JD, Bernet VJ, Rivera M, Thomas C, Kachergus JM, Necela BM, Hay ID, Westphal SA, Grant CS et al. 2015 Clinical and molecular features of Hurthle cell carcinoma of the thyroid. Journal of Clinical Endocrinology and Metabolism 100 55-62. (doi:10.1210/jc.2014-1634)
10. Choi J, Southworth LK, Sarin KY, Venteicher AS, Ma W, Chang W, Cheung P, Jun. S, Artandi MK, Shah N et al. 2008 TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. PLoS Genetics 4 e10. (doi:10.1371/journal.pgen. 0040010)
11. Codd V, Nelson CP, Albrecht E, Mangino M, Deelen J, Buxton JL, Hottenga JJ, Fischer K, Esko T, Surakka I et al. 2013 Identification of seven loci affecting mean telomere length and their association with disease. Nature Genetics 45 422-427. (doi:10.1038/ng.2528)
12. Crescenzi A, Trimboli P, Modica DC, Taffon C, Guidobaldi L, Taccogna S, Rainer A, Trombetta M, Papini E & Zelano G 2015 Preoperative assessment of TERT promoter mutation on thyroid core needle biopsies supports diagnosis of malignancy and addresses surgical strategy. Hormone and Metabolic Research [in press]. (doi:10.1055/s-0035-1548873)
13. DerSimonian R & Laird N 1986 Meta-analysis in clinical trials. Controlled Clinical Trials 7 177-188. (doi:10.1016/0197-2456 (86) 90046-2)
14. Dettmer MS, Schmitt A, Steinert H, Capper D, Moch H, Komminoth P & Perren A 2015 Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT. Endocrine-Related Cancer 22 419-429. (doi:10.1530/ERC-15-0057)
15. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J et al. 1995 The RNA component of human telomerase. Science 269 1236-1241. (doi:10.1126/science.7544491)
16. Gandolfi G, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A & Sancisi V 2015 TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. European Journal of Endocrinology 172 403-413. (doi:10.1530/EJE-14-0837)
17. Ghosh A, Saginc G, Leow SC, Khattar E, Shin EM, Yan TD, Wong M, Zhang Z, Li G, Sung WK et al. 2012 Telomerase directly regulates NFkB-dependent transcription. Nature Cell Biology 14 1270-1281. (doi:10.1038/ncb2621)
18. Gonzalez-Suarez E, Samper E, Ramirez A, Flores JM, Martin-Caballero J, Jorcano JL & Blasco MA 2001 Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO Journal 20 2619-2630. (doi:10.1093/emboj/20.11.2619)
19. Greider CW & Blackburn EH 2004 Tracking telomerase. Cell 116 S83-S86. (doi:10.1016/S0092-8674 (04) 00053-4)
20. Griewank KG, Murali R, Puig-Butille JA, Schilling B, Livingstone E, Potrony M, Carrera C, Schimming T, Möller I, Schwamborn M et al. 2014 TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. Journal of National Cancer Institute 106 pii: dju246. (doi:10.1093/jnci/dju246)
21. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW & Weinberg RA 1999 Creation of human tumour cells with defined genetic elements. Nature 400 464-468. (doi:10.1038/22780)
22. Hanahan D & Weinberg RA 2011 Hallmarks of cancer: the next generation. Cell 144 646-674. (doi:10.1016/j.cell.2011.02.013)
23. Harley CB & Villeponteau B 1995 Telomeres and telomerase in aging and cancer. Current Opinion in Genetics & Development 5 249-255. (doi:10.1016/0959-437X (95) 80016-6)
24. Higgins JP, Thompson SG, Deeks JJ & Altman DG 2003 Measuring inconsistency in meta-analyses. British Medical Journal 327 557-560. (doi:10.1136/bmj.327.7414.557)
25. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K et al. 2013 TERT promoter mutations in familial and sporadic melanoma. Science 339 959-961. (doi:10.1126/science. 1230062)
26. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, et al. 2015 SEER Cancer Statistics Review, 1975-2012, Bethesda, MD: National Cancer Institute, http://seer.cancer.gov/csr/1975-2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015. Accessed on October 25, 2015.
27. Hrdlickova R, Nehyba J & Bose HR Jr 2012 Alternatively spliced telomerase reverse transcriptase variants lacking telomerase activity stimulate cell proliferation. Molecular Cell Biology 32 4283-4296. (doi:10.1128/MCB. 00550-12)
28. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L & Garraway LA 2013 Highly recurrent TERT promoter mutations in human melanoma. Science 339 957-959. (doi:10.1126/science.1229259)
29. Hundahl SA, Fleming ID, Fremgen AM & Menck HR 1998 A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the US, 1985-1995 [see comments]. Cancer 83 2638-2648. (doi:10. 1002/(SICI) 1097-0142 (19981215) 83:12!2638::AID-CNCR31O3.0. CO;2-1)
30. Ito Y, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K & Miyauchi A 2005 Telomerase activity in thyroid neoplasms evaluated by the expression of human telomerase reverse transcriptase (hTERT). Anticancer Research 25 509-514.
31. Janknecht R 2004 On the road to immortality: hTERT upregulation in cancer cells. FEBS Letters 564 9-13. (doi:10.1016/S0014-5793 (04) 00356-4)
32. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC et al. 2013 TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. PNAS 110 6021-6026. (doi:10.1073/pnas.1303607110)
33. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL & Shay JW 1994 Specific association of human telomerase activity with immortal cells and cancer. Science 266 2011-2015. (doi:10.1126/science.7605428)
34. Koh CM, Khattar E, Leow SC, Liu CY, Muller J, Ang WX, Li Y, Franzoso G, Li S, Guccione E et al. 2015 Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity. Journal of Clinical Investigation 125 2109-2122. (doi:10.1172/JCI79134)
35. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA & Fagin JA 2013 Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. Journal of Clinical Endocrinology and Metabolism 98 E1562-E1566. (doi:10.1210/jc.2013-2383)
36. Lee YS, Kim Y, Jeon S, Bae JS, Jung SL & Jung CK 2015 Cytologic, clinicopathologic, and molecular features of papillary thyroid carcinoma with prominent hobnail features: 10 case reports and systematic literature review. International Journal of Clinical and Experimental Pathology 8 7988-7997.
37. Liu R & Xing M 2014 Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. Endocrine-Related Cancer 21 825-830. (doi:10.1530/ERC-14-0359)
38. Liu X, Wu G, Shan Y, Hartmann C, von Deimling A & Xing M 2013a Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle 12 1637-1638. (doi:10.4161/cc.24662)
39. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK & Xing M 2013b Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-Related Cancer 20 603-610. (doi:10.1530/ERC-13-0210)
40. Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C & Xu D 2014a The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 33 4978-4984. (doi:10.1038/onc.2013.446)
41. Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y et al. 2014b TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. Journal of Clinical Endocrinology and Metabolism 99 E1130-E1136. (doi:10.1210/jc. 2013-4048)
42. Low KC & Tergaonkar V 2013 Telomerase: central regulator of all of the hallmarks of cancer. Trends in Biochemical Sciences 38 426-434. (doi:10.1016/j.tibs.2013.07.001)
43. Mantel N & Haenszel W 1959 Statistical aspects of the analysis of data from retrospective studies of disease. Journal of National Cancer Institute 22 719-748.
44. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C et al. 2014 TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 99 E754-E765. (doi:10.1210/jc.2013-3734)
45. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q et al. 1997 hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90 785-795. (doi:10.1016/S0092-8674 (00) 80538-3)
46. Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, Meyne J, Ratliff RL & Wu JR 1988 A highly conserved repetitive DNA sequence, (TTAGGG) n, present at the telomeres of human chromosomes. PNAS 85 6622-6626. (doi:10.1073/pnas.85. 18.6622)
47. Muzza M, Colombo C, Rossi S, Tosi D, Cirello V, Perrino M, De Leo S, Magnani E, Pignatti E, Vigo B et al. 2015 Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization. Molecular and Cellular Endocrinology 399 288-295. (doi:10.1016/j.mce. 2014.10.019)
48. Ngeow J & Eng C 2014 TERT and BRAF in thyroid cancer: teaming up for trouble. Journal of Clinical Oncology 32 2683-2684. (doi:10.1200/JCO. 2014.56.5614)
49. Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, Gooding WE, Hodak SP, LeBeau SO, Ohori NP et al. 2014 Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer 120 3627-3634. (doi:10.1002/cncr.29038)
50. Nucera C 2013 Targeting thyroid cancer microenvironment: basic research and clinical applications. Frontiers in Endocrinology 4 167. (doi:10.3389/fendo.2013.00167)
51. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E et al. 2010 B-Raf (V600E) and thrombospondin-1 promote thyroid cancer progression. PNAS 107 10649-10654. (doi:10.1073/pnas.1004934107)
52. Nucera C, Lawler J & Parangi S 2011 BRAF (V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Research 71 2417-2422. (doi:10.1158/0008-5472. CAN-10-3844)
53. Qasem E, Murugan AK, Al-Hindi H, Xing M, Almohanna M, Alswailem M & Alzahrani AS 2015 TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population. Endocrine-Related Cancer 22 901-908. (doi:10.1530/ERC-15-0396)
54. Rafnar T, Sulem P, Stacey SN, Geller F, Gudmundsson J, Sigurdsson A, Jakobsdottir M, Helgadottir H, Thorlacius S, Aben KK et al. 2009 Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nature Genetics 41 221-227. (doi:10.1038/ng.296)
55. Saji M & Ringel MD 2010 The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Molecular and Cellular Endocrinology 321 20-28. (doi:10.1016/j.mce.2009.10.016)
56. Saji M, Xydas S, Westra WH, Liang CK, Clark DP, Udelsman R, Umbricht CB, Sukumar S & Zeiger MA 1999 Human telomerase reverse transcriptase (hTERT) gene expression in thyroid neoplasms. Clinical Cancer Research 5 1483-1489.
57. Sarin KY, Cheung P, Gilison D, Lee E, Tennen RI, Wang E, Artandi MK, Oro AE & Artandi SE 2005 Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature 436 1048-1052. (doi:10.1038/nature03836)
58. Shay JW & Bacchetti S 1997 A survey of telomerase activity in human cancer. European Journal of Cancer 33 787-791. (doi:10.1016/S0959-8049 (97) 00062-2)
59. Shi X, Liu R, Qu S, Zhu G, Bishop J, Liu X, Sun H, Shan Z, Wang E, Luo Y et al. 2015 Association of TERT promoter mutation 1, 295, 228 COT with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. Journal of Clinical Endocrinology and Metabolism 100 E632-E637. (doi:10.1210/jc.2014-3606)
60. Shi X, Liu R, Basolo F, Giannini R, Shen X, Teng D, Guan H, Shan Z, Teng W, Musholt TJ et al. 2016 Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. Journal of Clinical Endocrinology and Metabolism 101 264-274. (doi:10.1210/jc. 2015-2917)
61. Shrestha RT, Karunamurthy A, Amin K, Nikiforov YE & Caramori ML 2015 Multiple mutations detected preoperatively may predict aggressive behavior of papillary thyroid cancer and guide management - a case report. Thyroid 25 1375-1378. (doi:10.1089/thy.2015.0278)
62. Siegel R, Ma J, Zou Z & Jemal A 2014 Cancer statistics, 2014. CA: A Cancer Journal for Clinicians 64 9-29. (doi:10.3322/caac.21208)
63. Smith LL, Coller HA & Roberts JM 2003 Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nature Cell Biology 5 474-479. (doi:10.1038/ncb985)
64. Stewart SA, Hahn WC, O'Connor BF, Banner EN, Lundberg AS, Modha P, Mizuno H, Brooks MW, Fleming M, Zimonjic DB et al. 2002 Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. PNAS 99 12606-12611. (doi:10.1073/pnas.182407599)
65. Teng L, Specht MC, Barden CB & Fahey TJ III 2003 Antisense hTERT inhibits thyroid cancer cell growth. Journal of Clinical Endocrinology and Metabolism 88 1362-1366. (doi:10.1210/jc.2002-021222)
66. Umbricht CB, Saji M, Westra WH, Udelsman R, Zeiger MA & Sukumar S 1997 Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma. Cancer Research 57 2144-2147.
67. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L et al. 2013 Frequency of TERT promoter mutations in human cancers. Nature Communications 4 2185. (doi:10.1038/ncomms3185)
68. Wang Z, Zhu B, Zhang M, Parikh H, Jia J, Chung CC, Sampson JN, Hoskins JW, Hutchinson A, Burdette L et al. 2014a Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics 23 6616-6633. (doi:10.1093/hmg/ddu363)
69. Wang N, Liu T, Sofiadis A, Juhlin CC, Zedenius J, Hoog A, Larsson C & Xu D 2014b TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer 120 2965-2979. (doi:10.1002/cncr.28800)
70. Wang N, Xu D, Sofiadis A, Hoog A, Vukojevic V, Backdahl M, Zedenius J & Larsson C 2014c Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 99 E1571-E1579. (doi:10.1210/jc.2014-1158)
71. Wyatt HD, West SC & Beattie TL 2010 InTERTpreting telomerase structure and function. Nucleic Acids Research 38 5609-5622. (doi:10.1093/nar/gkq370)
72. Xing M 2005 BRAF mutation in thyroid cancer. Endocrine-Related Cancer 12 245-262. (doi:10.1677/erc.1.0978)
73. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocrine Reviews 28 742-762. (doi:10.1210/er.2007-0007)
74. Xing M 2010 Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 20 697-706. (doi:10.1089/thy.2010.1646)
75. Xing M 2013 Molecular pathogenesis and mechanisms of thyroid cancer. Nature Review Cancer 13 184-199. (doi:10.1038/nrc3431)
76. Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S & Bishop J 2014a BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. Journal of Clinical Oncology 32 2718-2726. (doi:10.1200/JCO.2014.55.5094)
77. Xing M, Liu R & Bishop J 2014b TERT promoter and BRAF mutations cooperatively promote papillary thyroid cancer-related mortality. Thyroid 24 (S1) A-131. (doi:10.1089/thy.2014.2410.abstracts.sc)